<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Tomohiro</forename><surname>Maniwa</surname></persName>
							<email>maniwa-to@mc.pref.osaka.jp.</email>
							<affiliation key="aff1">
								<orgName type="department">Department of General Thoracic Surgery</orgName>
								<orgName type="institution">Osaka International Cancer Center</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Yao Municipal Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yasushi</forename><surname>Shintani</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Thoracic Surgery Study Group of Osaka University</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of General Thoracic Surgery</orgName>
								<orgName type="institution">Osaka University Graduate School of Medicine</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jiro</forename><surname>Okami</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of General Thoracic Surgery</orgName>
								<orgName type="institution">Osaka International Cancer Center</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yoshihisa</forename><surname>Kadota</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Osaka Habikino Medical Center</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yukiyasu</forename><surname>Takeuchi</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Toneyama National Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Koji</forename><surname>Takami</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Osaka National Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hideoki</forename><surname>Yokouchi</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Suita Municipal Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eiji</forename><surname>Kurokawa</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Minoh City Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ryu</forename><surname>Kanzaki</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Thoracic Surgery Study Group of Osaka University</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of General Thoracic Surgery</orgName>
								<orgName type="institution">Osaka University Graduate School of Medicine</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yasushi</forename><surname>Sakamaki</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Osaka Police Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hiroyuki</forename><surname>Shiono</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Kindai University Nara Hospital</orgName>
								<address>
									<settlement>Nara</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Teruo</forename><surname>Iwasaki</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">JCHO Osaka Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kiyonori</forename><surname>Nishioka</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Kinki Central Hospital</orgName>
								<address>
									<settlement>Hyogo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ken</forename><surname>Kodama</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Thoracic Surgery</orgName>
								<orgName type="institution">Yao Municipal Hospital</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Meinoshin</forename><surname>Okumura</surname></persName>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Department of General Thoracic Surgery</orgName>
								<orgName type="institution">Osaka International Cancer Institute</orgName>
								<address>
									<addrLine>3-1-69 Otemae, Chuo-ku</addrLine>
									<postCode>541-8567</postCode>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department">Okumura M</orgName>
								<orgName type="laboratory">Thoracic Surgery Study Group of Osaka University</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D7BC59F0C80D084171B69B2923DB66EC</idno>
					<idno type="DOI">10.21037/jtd.2018.10.115</idno>
					<note type="submission">Submitted Aug 04, 2018. Accepted for publication Oct 17, 2018.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Non-small lung cancer</term>
					<term>lymph nodes</term>
					<term>survival</term>
					<term>surgery</term>
					<term>positron emission tomography (PET)</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Direct lymphatic drainage from a primary tumor to the right paratracheal or aortic window lymph nodes is often noted in pN2 disease.</s><s>This multi-institutional retrospective study investigated the outcomes of upfront surgery in patients with clinical skip N2 disease (N2 disease without N1 disease) and a tumor in the right upper lobe or left upper segment based on results of modern radiological examinations, including positron emission tomography (PET).</s><s>Methods: We identified 143 patients with cN2 disease who underwent upfront surgery in 12 institutions</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>The standard treatment of clinical N2 (cN2) non-small cell lung cancer (NSCLC) is chemoradiotherapy or induction therapy followed by surgery <ref type="bibr" target="#b0">(1,</ref><ref type="bibr" target="#b1">2)</ref>.</s><s>However, patients with resectable N2 disease occasionally undergo upfront surgery <ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref>.</s><s>In fact, a Japanese national database study revealed that 137 patients with cN2 pathological N2 (pN2) underwent surgery alone, 151 underwent upfront surgery followed by adjuvant chemotherapy, and 108 underwent induction therapy followed by surgery <ref type="bibr" target="#b5">(6)</ref>.</s><s>A recent report from the Society of Thoracic Surgeons Database showed that the number of clinical and pathological N2 (cN2pN2) patients who underwent upfront surgery was more than those who underwent induction therapy followed by surgery <ref type="bibr" target="#b6">(7)</ref>.</s></p><p><s>Meanwhile, several reports regarding surgery for pN2 disease have been published <ref type="bibr" target="#b7">(8)</ref><ref type="bibr" target="#b8">(9)</ref><ref type="bibr" target="#b9">(10)</ref>.</s><s>For instance, direct lymphatic drainage from a primary tumor to the right paratracheal or aortic window lymph nodes is often noted in pN2 disease <ref type="bibr" target="#b7">(8,</ref><ref type="bibr" target="#b8">9)</ref>.</s><s>N2 disease without N1 disease is known as "skip N2" disease.</s><s>Among patients with pN2 disease, those with skip N2 disease have a better prognosis than those with N1 and N2 disease <ref type="bibr" target="#b9">(10)</ref>.</s><s>However, few studies have been reported on clinical skip N2 disease based on results of modern radiological examinations, including positron emission tomography (PET).</s><s>In this multi-institutional retrospective study, we investigated the outcomes of upfront surgery in patients with c-skip N2 and a tumor in the right upper lobe or left upper segment based on results of modern radiological examinations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>In this study, data from 12 different thoracic surgery departments belonging to the Thoracic Surgery Study Group of Osaka University were analyzed.</s><s>In total, 6,042 patients underwent pulmonary resection for NSCLC between January 2006 and December 2013.</s><s>The inclusion criteria were as follows: (I) upfront surgery for cN2 NSCLC, (II) lobectomy or pneumonectomy, (III) systematic or lobe-specific lymph node dissection, (IV) cN2 NSCLC diagnosed via computed tomography (CT) and PET, and (V) curative resection.</s><s>Patients who underwent segmentectomy or wedge resection and those who only underwent lymph node sampling were excluded.</s><s>In this study, the patients were not necessarily diagnosed with pathological N2 via endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) or mediastinoscopy.</s></p><p><s>All patients with potentially resectable NSCLC underwent CT and PET before surgery.</s><s>The criterion for lymph node positivity was the shortest nodal diameter of ≥10 mm on CT <ref type="bibr" target="#b10">(11)</ref> or a metabolic activity of nodes higher than that of adjacent normal mediastinal and soft tissue on PET <ref type="bibr" target="#b11">(12)</ref>.</s><s>Patients with cN2 disease were diagnosed according to each institutional clinical conference or cancer board.</s></p><p><s>This study was a multi-institutional retrospective one, and operative indications for pulmonary resection were referred to each institution in detail.</s><s>Whether pulmonary resection was performed through thoracotomy or videoassisted thoracic surgery was decided on a case-to-cases basis and the judgment of the attending physician of each institution.</s><s>Follow-up varied in this study.</s><s>However, patient treatment was based on the guidelines for lung cancer stipulated by the Japan Lung Cancer Society.</s><s>The clinical and pathological stages were determined according to the 7th edition of the Union Internationale Contre le Cancer TNM staging system supported by the International Association for the Study of Lung Cancer <ref type="bibr" target="#b12">(13)</ref>.</s></p><p><s>The study protocol was approved by the institutional review boards of all participating hospitals, including that of the Ethics Committee of Osaka University Hospital (No. 16141) and Yao Municipal Hospital (H28-20).</s><s>Patients were duly informed of the decision-making process for the treatment.</s></p><p><s>Data on age, sex, smoking index, histology, carcinoembryonic antigen (CEA) (ng/mL), lung disease, cT status, tumor location, standardized uptake value (SUV) on PET, cN status, preoperative proven N2, pN status, surgical procedure, lymph node dissection, type of resection, epidermal growth factor receptor (EGFR) mutation status, adjuvant chemotherapy, molecular-targeted therapy, and overall survival (OS) were recorded and analyzed.</s><s>In addition, the following two criteria were used to categorize patients into the specific and nonspecific groups: (I) primary tumor in the right upper lobe or left upper segment and (II) c-skip N2 disease.</s><s>Thirty-nine patients who fulfilled the two criteria were categorized as the specific group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Associations among variables were analyzed using χ 2 and Student's t-tests.</s><s>OS was defined as the time between the date of pulmonary resection and date of death.</s><s>To identify prognostic factors after pulmonary resection, survival curves and survival rates (i.e., 5-year OS) were estimated using the Kaplan-Meier method.</s><s>Log-rank tests were used to compare survival across the levels of categorical variables.</s><s>To counteract the arbitrariness of choosing a threshold and dichotomizing, the effects of continuous variables on survival were also evaluated using Cox proportional hazards models.</s><s>In multivariate analyses of categoric variables, Cox proportional hazards models with the stepwise selection method were used.</s><s>All P values &lt;0.05 were considered statistically significant.</s><s>All statistical analyses were conducted using JMP software, version 9.0 (SAS Institute, Cary, NC, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Initially, data were obtained for 137 consecutive patients with cN2 disease who underwent upfront surgery at the 12 institutions.</s><s>After reviewing the data for eligibility, completeness, and consistency, patients with sarcomatoid carcinoma (n=3), those who had undergone segmentectomy (n=1), and those who had undergone R1/R2 resection (n=4) were excluded.</s><s>Among the remaining 129 patients, 94 who underwent PET were evaluated (Figure <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>The median follow-up time was 56.5 (range, 2-110) months.</s><s>Table <ref type="table" target="#tab_0">1</ref> shows the characteristics of the 94 patients who underwent upfront surgery for cN2 disease.</s><s>The cohort comprised 69 men and 25 women, and the median patient age was 66.5 (range, 35-80) years.</s><s>In total, 65 patients had adenocarcinoma and 29 had non-adenocarcinoma.</s><s>The tumor location was categorized as the right upper lobe or left upper segment (n=65, 69.1%) and others (n=29, 30.9%).</s><s>The median diameter of the mediastinal lymph node on CT was 13 (range, 5-30) mm, and the median SUV max of the mediastinal lymph node on PET was 3.9 (range, 1.7-16.8).</s><s>Of the 94 patients, 83 (88.3%) had clinical single N2 disease, 79 (84.0%) had N2 disease mode of lobe-specific spread <ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref>, and 50 (53.2%)</s><s>had N2 disease without N1 (i.e., skip N2 disease).</s><s>Only two patients were pathologically diagnosed with N2 via EBUS-TBNA before surgery.</s></p><p><s>Table <ref type="table" target="#tab_2">2</ref> shows the surgical procedure, pathological N status, and postoperative therapy of the patients.</s><s>In total, 22 patients (23.4%) had clinical N2 and pathological N0 or N1 (cN2pN0/1) and 70 (74.5%)</s><s>had cN2pN2.</s><s>Of the 70 patients with cN2pN2 disease, 41 (58.6%) had pathologically single N2 disease, and 39 patients (55.7%) received adjuvant chemotherapy.</s><s>Seventeen patients had EGFR mutation and 20 received molecular-targeted therapy throughout survival.</s></p><p><s>Figure <ref type="figure" target="#fig_3">2</ref> shows OS of all patients who underwent upfront surgery for cN2.</s><s>The 5-year OS rate for patients with cN2 was 47.9%.</s><s>Figure <ref type="figure" target="#fig_2">3</ref> shows OS in the cN2pN0/1 and cN2pN2 group.</s><s>The 5-year OS rates for cN2pN0/pN1 and cN2pN2 were 74.9% and 41.2%, respectively (P=0.034).</s></p><p><s>Table <ref type="table" target="#tab_3">3</ref> shows the results of the univariate analysis of the 5-year OS for patients who underwent upfront surgery for cN2 disease.</s><s>No significant differences in age, sex, smoking history, histology, CEA level, tumor size, and clinical lymph node were noted when these parameters were dichotomized, but patients in Group A had a significantly better prognosis than those in Group B (P=0.039).</s></p><p><s>Table <ref type="table" target="#tab_6">4</ref> shows multivariate analysis using a Cox proportional hazards model.</s><s>In the multivariate analysis, tumor diameter, CEA level, multiple N2, and histological finding were not significant prognostic factors, but Group A was a significant prognostic factor (P=0.030).</s></p><formula xml:id="formula_0"> Clinical skip N2  Tumor in upper lobe Excluded  Not received PET (n=38)  Sarcomatoid carcinoma (n=3)  R1/2 (n=4)  Segmentectomy (n=1)</formula><p><s>Table <ref type="table" target="#tab_7">5</ref> shows the comparison data between patients in the specific and nonspecific groups.</s><s>No significant difference in age, sex, smoking history, histology, CEA level, or tumor size was noted between the two groups.</s><s>However, the proportion of patients with p-skip N2 disease tended to be higher in the specific group than in the nonspecific group (P=0.086).</s><s>No difference in pN was noted between the two groups.</s></p><p><s>Figure <ref type="figure" target="#fig_4">4</ref> shows OS in Group A and Group B. The 5-year OS rates for Group A (n=39) and Group B (n=55) were 64.0% and 37.0%, respectively (P=0.039).</s></p><p><s>Figure <ref type="figure" target="#fig_5">5</ref> shows OS of patients who had a tumor in the right upper lobe or left upper segment.</s><s>The 5-year OS rates for the c-skip N2 group (n=39) and non-skip N2 group (n=25) were 64.0% and 40.1%, respectively (P=0.26).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In this study, we revealed that patients with cN2 disease in the specific group had a more favorable prognosis and that upfront surgery may be a treatment option for such selected patients with NSCLC in the specific group.</s><s>Patients with cN2 NSCLC have poor survival rates after tumor resection <ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref><ref type="bibr" target="#b17">(18)</ref>.</s><s>Some studies have reported the outcomes of chemotherapy or chemoradiotherapy followed by surgery in a clinical trial setting <ref type="bibr" target="#b18">(19,</ref><ref type="bibr" target="#b19">20)</ref>; however, the role of surgery in treating cN2 disease remains controversial.</s><s>Furthermore, concurrent chemoradiotherapy for stage IIIA NSCLC resulted in an approximately 15-20% 5-year OS <ref type="bibr" target="#b20">(21,</ref><ref type="bibr" target="#b21">22)</ref>.</s></p><p><s>Based on these results, guidelines in Western countries (1,2) recommend chemoradiotherapy for patients with cN2 stage IIIA NSCLC.</s><s>Induction therapy followed by surgery is among the treatment options in a clinical trial.</s><s>However, patients with resectable N2 disease sometimes undergo upfront surgery.</s><s>In fact, there are several reports on upfront surgery for such patients <ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref><ref type="bibr" target="#b4">(5)</ref>.</s><s>However, no large-scale study has reported whether modern radiologic examinations, including PET, improved treatment outcomes     of surgery for cN2 disease.</s><s>Thus, we evaluated the current treatment outcomes of upfront surgery for cN2 disease.</s></p><p><s>PET has been widely used as a preoperative examination modality for lung cancer in the past decade.</s><s>This study was designed to assess the treatment outcomes in patients for whom PET was used as a preoperative examination.</s><s>PET is useful for assessing metastasis of the mediastinal lymph node, and a meta-analysis indicated that the accuracy of PET in diagnosing mediastinal lymph node metastasis ranged from 71% to 85% <ref type="bibr" target="#b11">(12)</ref>.</s><s>In the present study, the accuracy of PET in detecting mediastinal lymph node metastasis is 74.4%, which is similar to that previously reported.</s><s>Notably, in terms of patients with cN2pN2 disease, the prevalence (74.4%) of pathological N2 disease found in this study was higher than that found in a  previous study (46.3%) <ref type="bibr" target="#b4">(5)</ref>.</s><s>In addition, the prevalence of pathological single N2 disease in this study was higher than that in previous reports <ref type="bibr" target="#b3">(4,</ref><ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17)</ref>.</s><s>We believe that this result can be attributed to the use of PET as a diagnostic modality in our study.</s></p><p><s>Several studies have demonstrated that patients with pathological skip N2 have a better prognosis (8-10); however, few reports about clinical skip N2 have been published.</s><s>In this study, of 44 patients with clinical skip   N2, 26 (59.1%) had pathological skip N2.</s><s>Moreover, of 39 patients in the specific group, 25 (64.1%) had pathological N2 disease and 13 (52.0%)</s><s>had pathological skip N2.</s><s>As a result, the 5-year OS of patients with cN2 and cN2pN2 in the specific group were 64.0% and 54.5%, respectively.</s><s>The prevalence of pathological N2 disease in Group A was higher than that in Group B but the pathological N factor did not differ significantly between the two groups.</s><s>Univariate analysis for the 5-year OS revealed that patients in Group A had a significantly better prognosis than those in Group B (P=0.039).</s><s>Moreover, multivariate analysis showed that Group A was a significant prognostic factor (P=0.030).</s><s>Therefore, we think that our results about upfront surgery for selective cN2 disease may have considerable importance.</s></p><p><s>Some studies <ref type="bibr" target="#b22">(23)</ref><ref type="bibr" target="#b23">(24)</ref><ref type="bibr" target="#b24">(25)</ref> have identified distinct patterns of metastatic spread through the lymphatic pathway, which are dependent on the location of primary tumors.</s><s>Aokage et al. <ref type="bibr" target="#b23">(24)</ref> reported that upper lobe tumors with subcarinal metastasis were also associated with a poor 5-year survival rate of 9.1%.</s><s>We assume that patients with upper lobe tumors and subcarinal metastasis already have systemic disease.</s><s>In this study, only 3 patients had upper lobe tumors with subcarinal metastasis; of these patients, 2 had recurrences within 1 year.</s></p><p><s>Induction therapy has several potential advantages, such as increased tumor sensitivity to chemotherapy, decreased tumor volume to enable better local control after subsequent surgery, rapid eradication of clinically undetected micrometastases, and better tolerance and compliance than postsurgical treatments <ref type="bibr" target="#b25">(26)</ref>.</s><s>However, induction therapy also has the disadvantage of increasing the likelihood of postoperative complications.</s><s>This disadvantage may be negated, however, if initial surgery is performed for patients with cN2 disease.</s></p><p><s>Before induction therapy, patients must undergo invasive examinations such as EBUS-TBNA, mediastinoscopy, or video-assisted thoracotomy.</s><s>The tumors should be pathologically confirmed as N2 disease.</s><s>However, such invasive examinations are also associated with complications, require additional hospital time, and incur more costs to the patient before surgery <ref type="bibr" target="#b26">(27)</ref>.</s><s>In this study, of the 94 patients with cN2 disease, 22 had false-positive N2 disease.</s><s>If patients with false-positive N2 received EBUS of the mediastinal lymph nodes, then they might have been identified with N0 or N1 before surgery.</s></p><p><s>Immunotherapy, immune check point therapy targeting programmed death receptor ligand (PD-L1), for nonsurgical NSCLC was effective <ref type="bibr" target="#b27">(28)</ref>.</s><s>PD-L1 expression by tumor or immune cells is an important biomarker for predicting treatment response.</s><s>However, a significant proportion of patients with a diagnosis of lung adenocarcinoma present a heterogeneous staining pattern for PD-L1 <ref type="bibr" target="#b28">(29)</ref>.</s><s>Therefore, it is worthwhile to get an entire sample by upfront surgery rather than obtaining a sample by biopsy.</s></p><p><s>Although multimodality treatment is recommended for patients with N2 disease, such an approach will be difficult for elderly patients or those with a poor performance status.</s><s>Moreover, patients with interstitial pneumonia or severe emphysema are not eligible for chemoradiotherapy or radiotherapy because of an increased risk for respiratory failure.</s><s>In clinical practice, high-risk patients should be treated via surgical treatment alone or given the best palliative care.</s><s>Hence, surgical treatment is sometimes unavoidable for these patients.</s><s>In the present study, of 70 patients with cN2pN2, 11 (15.7%) were aged &gt;75 years and 25 (35.7%) had severe pulmonary diseases such as emphysema or interstitial pneumonia.</s><s>As result, only 31 patients (44.2%) did not receive adjuvant chemotherapy.</s></p><p><s>Molecular-targeted therapy for NSCLC has drastically improved patient survival.</s><s>Among patients with EGFR mutation-positive cancer, those who receive EGFR tyrosine kinase inhibitor had better progression-free survival than those who received standard chemotherapy <ref type="bibr" target="#b29">(30,</ref><ref type="bibr" target="#b30">31)</ref>.</s><s>In the present study, 17 (18.9%)</s><s>patients had EGFR mutationpositive cancer, and 20 patients (21.3%) received moleculartargeted therapy for postoperative recurrence.</s><s>As shown in Figure <ref type="figure" target="#fig_3">2</ref>, this may be associated with the better prognosis observed in this study than those in previous reports.</s></p><p><s>This study had some limitations that should be considered when interpreting the results.</s><s>First, this was a retrospective multicenter cohort study, which included various biases.</s><s>Patient selection bias cannot be excluded, as mentioned previously.</s><s>Upfront surgery was performed according to the judgment of members of each individual institute, but it was performed following fulfilment of criteria that were based on protocols.</s><s>Second, no control group with the same background was set for comparison.</s><s>To clarify the superiority of upfront surgery to standard chemoradiotherapy for patients with specific cN2 disease, a prospective randomized trial is necessary.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Upfront surgery might be acceptable as a treatment option for selected patients with cN2 disease.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Study design and participants.</s><s>NSCLC, non-small cell lung cancer; TSSGO, Thoracic Surgery Study Group of Osaka University, Major resection: lobectomy or pneumonectomy; MLND, systematic mediastinal lymph node dissection or lobespecific lymph node dissection.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>6,042 patients pulmonary resection for NSCLC between 2006 and 2013 from 12 institutions in TSSGO 140 enrolled patients (I) Upfront surgery in patients with clinical N2 (II) Major resection and MLND (III) clinical N2 by CT and PET 94 eligible patients Group A (n=39) Group B (n=55)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Overall survival (OS) in the cN2pN0/1 and cN2pN2 groups.</s><s>The 5-year OS rates of the cN2pN0/pN1 (n=22) and cN2pN2 (n=70) groups were 74.9% and 41.2%, respectively (P=0.034).</s><s>The median OS for patients with cN2pN2 was 48 months.</s><s>OS, overall survival.</s></p></div></figDesc><graphic coords="5,341.14,300.61,178.38,128.70" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 OS in all patients who underwent upfront surgery for cN2.</s><s>The 5-year OS rate was 47.9%, and the median OS was 58 months.</s><s>OS, overall survival.</s></p></div></figDesc><graphic coords="5,340.66,86.32,180.90,123.84" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure4OS in Group A and Group B. The 5-year OS rates of Group A (n=39) and Group B (n=55) groups were 64.0% and 37.0%, respectively (P=0.039).</s><s>The median OS for patients with cN2 was 87 and 48 months in Group A and Group B groups, respectively.</s><s>OS, overall survival.</s></p></div></figDesc><graphic coords="7,346.89,327.31,171.36,117.90" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5</head><label>5</label><figDesc><div><p><s>Figure 5 OS of patients who had a tumor in the right upper lobe or left upper segment.</s><s>The 5-year OS rates for the c-skip N2 group (n=39) and non-skip N2 group (n=25) were 64.0% and 40.1%, respectively (P=0.26).</s><s>OS, overall survival.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Characteristics of patients who underwent upfront surgery for N2 disease</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell>n (%)</cell></row><row><cell>Age</cell><cell>66.5 [35-80]</cell></row><row><cell>Sex</cell><cell></cell></row><row><cell>Male</cell><cell>69 (73.4)</cell></row><row><cell>Female</cell><cell>25 (26.6)</cell></row><row><cell>Smoking</cell><cell></cell></row><row><cell>Smoker</cell><cell>76 (80.8)</cell></row><row><cell>Non-smoker</cell><cell>18 (19.1)</cell></row><row><cell>Smoking index</cell><cell>855 [0-2,850]</cell></row><row><cell>CEA (ng/mL)</cell><cell>4.0 (0.3-182)</cell></row><row><cell>Lung disease</cell><cell></cell></row><row><cell>Intestinal pneumonia</cell><cell>12 (12.8)</cell></row><row><cell>Emphysema</cell><cell>19 (20.2)</cell></row><row><cell>Tumor diameter</cell><cell>32 [10-100]</cell></row><row><cell>Lymph node diameter</cell><cell>13 [5-30]</cell></row><row><cell>SUV max on PET</cell><cell></cell></row><row><cell>Tumor</cell><cell>9.6 (2-22.5)</cell></row><row><cell>Lymph node</cell><cell>3.9 (1.7-16.8)</cell></row><row><cell>Tumor location</cell><cell></cell></row><row><cell>RUL</cell><cell>39 (41.5)</cell></row><row><cell>RML</cell><cell>2 (2.1)</cell></row><row><cell>RML</cell><cell>17 (18.3)</cell></row><row><cell>LUL (upper segment)</cell><cell>25 (26.6)</cell></row><row><cell>LUL (lingular segment)</cell><cell>4 (4.3)</cell></row><row><cell>LLL</cell><cell>7 (7.4)</cell></row><row><cell>cT</cell><cell></cell></row><row><cell>cT1a</cell><cell>9 (9.6)</cell></row><row><cell>cT1b</cell><cell>21 (22.3)</cell></row><row><cell>cT2a</cell><cell>40 (42.6)</cell></row><row><cell>cT2b</cell><cell>13 (13.8)</cell></row><row><cell>cT3</cell><cell>9 (9.6)</cell></row><row><cell>cT4</cell><cell>2 (2.1)</cell></row><row><cell>Histology</cell><cell></cell></row><row><cell>Ad</cell><cell>65 (69.1)</cell></row><row><cell>Non-ad</cell><cell>29 (30.9)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 (</head><label>1</label><figDesc><div><p><s>continued)</s></p></div></figDesc><table><row><cell>Table 1 (continued)</cell><cell></cell></row><row><cell>Characteristics</cell><cell>n (%)</cell></row><row><cell>Clinical N2 station</cell><cell></cell></row><row><cell>Single</cell><cell>83 (88.3)</cell></row><row><cell>Multiple</cell><cell>11 (11.7)</cell></row><row><cell>c-skip N2</cell><cell></cell></row><row><cell>Without N1</cell><cell>50 (53.2)</cell></row><row><cell>With N1</cell><cell>44 (46.8)</cell></row><row><cell>Preoperative proven pathological N2</cell><cell></cell></row><row><cell>+</cell><cell>2 (2.1)</cell></row><row><cell>−</cell><cell>92 (97.9)</cell></row><row><cell cols="2">SUV max on PET, standardized uptake value on positron</cell></row><row><cell cols="2">emission tomography; RUL, right upper lobe; RML, right middle</cell></row><row><cell cols="2">lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower</cell></row><row><cell cols="2">lobe; c-skip N2, clinical N2 disease without N1.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p><s>Pathological finding and, postoperative course</s></p></div></figDesc><table><row><cell>Factors</cell><cell>n (%)</cell></row><row><cell>Surgical procedure</cell><cell></cell></row><row><cell>Lobectomy</cell><cell>85 (90.4)</cell></row><row><cell>Bi-Lobectomy</cell><cell>3 (3.2)</cell></row><row><cell>Pneumonectomy</cell><cell>6 (6.4)</cell></row><row><cell>Lymph node dissection</cell><cell></cell></row><row><cell>Lobe-specific lymph node dissection</cell><cell>12 (12.8)</cell></row><row><cell>Systematic lymph node dissection</cell><cell>82 (87.2)</cell></row><row><cell>pN</cell><cell></cell></row><row><cell>pN0</cell><cell>21 (22.3)</cell></row><row><cell>pN1</cell><cell>1 (1.0)</cell></row><row><cell>pN2</cell><cell>70 (74.5)</cell></row><row><cell>pN3</cell><cell>2 (2.1)</cell></row><row><cell>pN2 station</cell><cell></cell></row><row><cell>Single</cell><cell>41 (58.6)</cell></row><row><cell>Multiple</cell><cell>29 (41.4)</cell></row><row><cell>p-skip N2</cell><cell></cell></row><row><cell>without N1</cell><cell>27 (38.6)</cell></row><row><cell>with N1 (+)</cell><cell>43 (61.4)</cell></row><row><cell>EGFR mutation</cell><cell></cell></row><row><cell>+</cell><cell>17 (18.9)</cell></row><row><cell>−</cell><cell>45 (47.9)</cell></row><row><cell>NA</cell><cell>33 (35.1)</cell></row><row><cell>Adjuvant Cx</cell><cell></cell></row><row><cell>+</cell><cell>45 (47.8)</cell></row><row><cell>CDDP + VNR</cell><cell>16</cell></row><row><cell>CBDCA + PTX</cell><cell>13</cell></row><row><cell>UFT</cell><cell>6</cell></row><row><cell>Others</cell><cell>10</cell></row><row><cell>−</cell><cell>49 (52.2)</cell></row><row><cell>Receiving molecular targeted therapy</cell><cell></cell></row><row><cell>+</cell><cell>20 (21.3)</cell></row><row><cell>−</cell><cell>74 (78.7)</cell></row><row><cell cols="2">p-skip N2, pathological N2 disease without N1; NA, not</cell></row></table><note><p><s>available; CDDP + VNR, Cisplatin + Vinorelbin; CBDCA + PTX, Carboplatin + Paclitaxel; UFT, Uracil-Tegafur; EGFR, epidermal growth factor receptor.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc><div><p><s>Univariate analysis of the overall survival for patients who underwent initial surgery for clinical N2 disease</s></p></div></figDesc><table><row><cell>Variables</cell><cell>n</cell><cell>5 year-OS</cell><cell>MST (M)</cell><cell>P value</cell></row><row><cell>Age</cell><cell></cell><cell></cell><cell></cell><cell>0.58</cell></row><row><cell>70≥</cell><cell>60</cell><cell>50.4</cell><cell>70</cell><cell></cell></row><row><cell>70&lt;</cell><cell>34</cell><cell>43.7</cell><cell>53</cell><cell></cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell></cell><cell>0.68</cell></row><row><cell>Male</cell><cell>69</cell><cell>47.2</cell><cell>56</cell><cell></cell></row><row><cell>Female</cell><cell>25</cell><cell>49.4</cell><cell>58</cell><cell></cell></row><row><cell>CEA (ng/mL)</cell><cell></cell><cell></cell><cell></cell><cell>0.55</cell></row><row><cell>≤5</cell><cell>55</cell><cell>46.5</cell><cell>56</cell><cell></cell></row><row><cell>5&lt;</cell><cell>39</cell><cell>50.6</cell><cell>64</cell><cell></cell></row><row><cell>cT</cell><cell></cell><cell></cell><cell></cell><cell>0.39</cell></row><row><cell>cT1</cell><cell>30</cell><cell>54.0</cell><cell>70</cell><cell></cell></row><row><cell>cT2-4</cell><cell>64</cell><cell>41.8</cell><cell>56</cell><cell></cell></row><row><cell>SUV max on PET</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Primary</cell><cell></cell><cell></cell><cell></cell><cell>0.47</cell></row><row><cell>≤9.6</cell><cell>36</cell><cell>49.3</cell><cell>51</cell><cell></cell></row><row><cell>9.6&lt;</cell><cell>38</cell><cell>49.2</cell><cell>56</cell><cell></cell></row><row><cell cols="2">No data available 20</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lymph node</cell><cell></cell><cell></cell><cell></cell><cell>0.16</cell></row><row><cell>≤4.0</cell><cell>35</cell><cell>58.8</cell><cell>87</cell><cell></cell></row><row><cell>4.0&lt;</cell><cell>28</cell><cell>36.8</cell><cell>48</cell><cell></cell></row><row><cell cols="2">No data available 31</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Histology</cell><cell></cell><cell></cell><cell></cell><cell>0.98</cell></row><row><cell>Ad</cell><cell>65</cell><cell>46.3</cell><cell>56</cell><cell></cell></row><row><cell>Non-Ad</cell><cell>29</cell><cell>52.1</cell><cell>87</cell><cell></cell></row><row><cell>cN2</cell><cell></cell><cell></cell><cell></cell><cell>0.40</cell></row><row><cell>c-single N2</cell><cell>81</cell><cell>50.3</cell><cell>64</cell><cell></cell></row><row><cell>c-multiple N2</cell><cell>13</cell><cell>35.9</cell><cell>53</cell><cell></cell></row><row><cell>Group</cell><cell></cell><cell></cell><cell></cell><cell>0.039</cell></row><row><cell>Group A</cell><cell>39</cell><cell>64.0</cell><cell>87</cell><cell></cell></row><row><cell>Group B</cell><cell>55</cell><cell>37.0</cell><cell>48</cell><cell></cell></row><row><cell>Surgical procedure</cell><cell></cell><cell></cell><cell></cell><cell>0.039</cell></row><row><cell>Lobectomy</cell><cell>85</cell><cell>50.1</cell><cell>64</cell><cell></cell></row><row><cell>Bi-lobectomy</cell><cell>3</cell><cell>66.7</cell><cell>87</cell><cell></cell></row><row><cell>Pneumonectomy</cell><cell>6</cell><cell>0</cell><cell>26</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3</head><label>3</label><figDesc><div><p><s>(continued)</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3</head><label>3</label><figDesc><div><p><s>(continued)</s></p></div></figDesc><table><row><cell>Variables</cell><cell>n</cell><cell>5 year-OS</cell><cell>MST (M)</cell><cell>P value</cell></row><row><cell>pN</cell><cell></cell><cell></cell><cell></cell><cell>0.034</cell></row><row><cell>pN0,1</cell><cell>22</cell><cell>74.9</cell><cell>−</cell><cell></cell></row><row><cell>pN2</cell><cell>70</cell><cell>41.0</cell><cell>48</cell><cell></cell></row><row><cell cols="5">Group A: primary tumor in right upper lobe or left upper</cell></row><row><cell cols="5">segment, N2 disease without N1; Group B: others. SUV,</cell></row><row><cell cols="5">standardized uptake value; CEA, carcinoembryonic antigen;</cell></row><row><cell cols="3">PET, positron emission tomography.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4</head><label>4</label><figDesc><div><p><s>Multivariate analysis of the overall survival using a Cox proportional hazards model for patients who underwent initial surgery for clinical N2 disease</s></p></div></figDesc><table><row><cell>Variables</cell><cell>HR</cell><cell>95% CI</cell><cell>P value</cell></row><row><cell>Tumor</cell><cell></cell><cell></cell><cell></cell></row><row><cell>&gt;3.0 versus ≤3.0 cm</cell><cell>1.42</cell><cell>0.73-2.87</cell><cell>0.31</cell></row><row><cell>Single N2</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Multiple N2 versus</cell><cell>1.47</cell><cell>0.60-3.28</cell><cell>0.38</cell></row><row><cell>single N2</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CEA</cell><cell></cell><cell></cell><cell></cell></row><row><cell>High versus normal</cell><cell>1.09</cell><cell>0.59-2.05</cell><cell>0.78</cell></row><row><cell>Histology</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ad versus Sq</cell><cell>1.09</cell><cell>0.53-2.32</cell><cell>0.82</cell></row><row><cell>Group</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Group B versus Group A 1.99</cell><cell>1.06-3.91</cell><cell>0.030</cell></row><row><cell cols="2">CEA, carcinoembryonic antigen.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 5</head><label>5</label><figDesc><div><p><s>The comparison the specific group with the non-specific group</s></p></div></figDesc><table><row><cell>Factors</cell><cell cols="2">Group A (n=39) Group B (n=55)</cell><cell>P value</cell></row><row><cell>Age</cell><cell>66 [35-79]</cell><cell>67 [44-80]</cell><cell>0.94</cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell>0.09</cell></row><row><cell>Male</cell><cell>25</cell><cell>44</cell><cell></cell></row><row><cell>Female</cell><cell>14</cell><cell>11</cell><cell></cell></row><row><cell>Smoking</cell><cell></cell><cell></cell><cell>0.32</cell></row><row><cell>Smoker</cell><cell>30</cell><cell>46</cell><cell></cell></row><row><cell>Non-smoker</cell><cell>9</cell><cell>8</cell><cell></cell></row><row><cell>Tumor size (mm)</cell><cell>35 [10-59]</cell><cell>31 [11-100]</cell><cell>0.24</cell></row><row><cell>LN size (mm)</cell><cell>14 [5-30]</cell><cell>12 [6-30]</cell><cell>0.74</cell></row><row><cell>SUV max:</cell><cell>9.3 (2-22.1)</cell><cell>9.7 (2.6-22.5)</cell><cell>0.12</cell></row><row><cell>primary</cell><cell></cell><cell></cell><cell></cell></row><row><cell>SUV max: LN</cell><cell>3.4 [2-16]</cell><cell>4.0 (1.7-16.8)</cell><cell>0.52</cell></row><row><cell>Histology</cell><cell></cell><cell></cell><cell>0.98</cell></row><row><cell>Ad</cell><cell>27</cell><cell>38</cell><cell></cell></row><row><cell>Non-ad</cell><cell>12</cell><cell>17</cell><cell></cell></row><row><cell>CEA (ng/mL)</cell><cell>4.1 (0.3-90.0)</cell><cell>4.0 (0.7-182.0)</cell><cell>0.53</cell></row><row><cell>pN</cell><cell></cell><cell></cell><cell>0.15</cell></row><row><cell>pN0,1</cell><cell>12</cell><cell>10</cell><cell></cell></row><row><cell>pN2,3</cell><cell>27</cell><cell>45</cell><cell></cell></row><row><cell>p-skip N2</cell><cell></cell><cell></cell><cell>0.086</cell></row><row><cell>Without N1</cell><cell>13</cell><cell>14</cell><cell></cell></row><row><cell>With N1</cell><cell>12</cell><cell>31</cell><cell></cell></row><row><cell>p-single N2</cell><cell></cell><cell></cell><cell>0.75</cell></row><row><cell>p-single N2</cell><cell>14</cell><cell>27</cell><cell></cell></row><row><cell>p-multiple N2</cell><cell>11</cell><cell>18</cell><cell></cell></row><row><cell>EGFR mutation</cell><cell></cell><cell></cell><cell>0.50</cell></row><row><cell>(+)</cell><cell>5</cell><cell>12</cell><cell></cell></row><row><cell>(−)</cell><cell>20</cell><cell>24</cell><cell></cell></row><row><cell>NA</cell><cell>14</cell><cell>19</cell><cell></cell></row><row><cell cols="2">Adjuvant chemotherapy</cell><cell></cell><cell>0.48</cell></row><row><cell>(+)</cell><cell>17</cell><cell>28</cell><cell></cell></row><row><cell>(−)</cell><cell>22</cell><cell>27</cell><cell></cell></row><row><cell cols="4">SUV, standardized uptake value; LN, lymph node; CEA,</cell></row><row><cell cols="2">carcinoembryonic antigen.</cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© Journal of Thoracic Disease. All rights reserved.J Thorac Dis 2018;10(12):6828-6837</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© Journal of Thoracic Disease. All rights reserved.J Thorac Dis 2018;10(12):6828-6837 jtd.amegroups.com</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© Journal of Thoracic Disease. All rights reserved.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>None.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Footnote</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of Interest:</head><p><s>The authors have no conflicts of interest to declare.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical Statement:</head><p><s>The study protocol was approved by the institutional review boards of all participating hospitals, including that of the Ethics Committee of Osaka University Hospital (No. 16141) and Yao Municipal Hospital (H28-20).</s><s>Patients were duly informed of the decision-making process for the treatment.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ramnath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Dilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="e314S" to="340S" />
			<date type="published" when="2013">2013</date>
			<publisher>American College of Chest Physicians</publisher>
		</imprint>
	</monogr>
	<note>evidence-based clinical practice guidelines</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vansteenkiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Ruysscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eberhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="89" to="98" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Outcomes of initial surgery in patients with clinical N2 non-small cell lung cancer who met 4 specific criteria</title>
		<author>
			<persName><forename type="first">T</forename><surname>Maniwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Isaka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surg Today</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="699" to="704" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved</title>
		<author>
			<persName><forename type="first">T</forename><surname>Matsunaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takamochi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="86" to="91" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Surgical outcomes after initial surgery for clinical single-station N2 non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hishida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ohe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jpn J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="85" to="92" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Surgical outcome of stage IIIA-cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004</title>
		<author>
			<persName><forename type="first">I</forename><surname>Yoshino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Miyaoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="850" to="855" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Surgically managed clinical stage IIIA-clinical N2 lung cancer in The Society of Thoracic Surgeons Database</title>
		<author>
			<persName><forename type="first">D</forename><surname>Boffa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Thorac Surg</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="395" to="403" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe</title>
		<author>
			<persName><forename type="first">M</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sawabata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Takeda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1100" to="1106" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Eastern Cooperative Oncology Group.Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Vangel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wagner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="130" to="137" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Misthos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sepsas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Athanassiadi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cardiothorac Surg</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="502" to="508" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Glazer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Quint</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AJR Am J Roentgenol</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="261" to="265" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/ computed tomography for the detection of metastases in non-small-cell lung cancer patients</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="E37" to="47" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours</title>
		<author>
			<persName><forename type="first">P</forename><surname>Goldstraw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crowley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chansky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="706" to="714" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Results of surgical treatment in N2 lung cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Martini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Flehinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Zaman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Surg</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="663" to="666" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Delarue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ilves</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status</title>
		<author>
			<persName><forename type="first">K</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nagai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yoshida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="145" to="153" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications</title>
		<author>
			<persName><forename type="first">F</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Grunenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Pignon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2981" to="2989" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rosell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gómez-Codina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Camps</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">330</biblScope>
			<biblScope unit="page" from="153" to="158" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Albain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Swann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Rusch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page">37986</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Van Meerbeeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Schil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="442" to="450" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Phase III study comparing second-and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105</title>
		<author>
			<persName><forename type="first">N</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nishimura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="3739" to="3745" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: longterm follow-up results</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kubota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fukuoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Japan Clinical Oncology Group Protocol</title>
		<imprint>
			<biblScope unit="volume">8902</biblScope>
			<biblScope unit="page" from="445" to="450" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>Ann Oncol</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Okada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tsubota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yoshimura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="949" to="953" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Subcarinal lymph node in upper lobe non-small cell lung cancer patients: is selective lymph node dissection valid?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Aokage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ishii</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="163" to="167" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Has lobe-specific nodal dissection for early-stage non-small lung cancer already become standard treatment?</title>
		<author>
			<persName><forename type="first">T</forename><surname>Maniwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kodama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Dis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="2407" to="2410" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data</title>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">383</biblScope>
			<biblScope unit="page" from="1561" to="1571" />
			<date type="published" when="2014">2014</date>
		</imprint>
		<respStmt>
			<orgName>NSCLC Meta-analysis Collaborative Group</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Invasive mediastinal staging is irrelevant for PET/CT positive N2 lung cancer if the primary tumour and ipsilateral lymph nodes are resectable</title>
		<author>
			<persName><forename type="first">E</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Mcelnay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rocco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir Med</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="e32" to="33" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Reck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rodríguez-Abreu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1823" to="1833" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: impact of the architecture pattern and the number of cores</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gagné</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Enlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pigeon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="687" to="694" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maemondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kobayashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="2380" to="2388" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mitsudomi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Morita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yatabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="121" to="128" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
